GlassScriptPhysician profile
Mark Jeffrey Berger
NPI 1891861589
$443.90
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $44.61 · 2021: $302 · 2022: $97.39.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Integra Lifesciences Corporation | $247.02 | 2021 | |
| Organogenesis INC. | $95.67 | 2021-2022 | |
| Nabriva Therapeutics, Plc | $28.85 | 2021-2022 | |
| Boston Scientific Corporation | $17.55 | 2019 | |
| Paragon 28, INC. | $14.74 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $14.22 | 2022 | |
| Alfasigma USA, INC. | $13.53 | 2021 | |
| Sebela Pharmaceuticals INC. | $12.32 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.